EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis

Yu-Min Lin, Jheng-Yan Wu, Mei-Chuan Lee, Chen-Lun Su, Han Siong Toh, Wei-Ting Chang, Sih-Yao Chen, Fang-Hsiu Kuo, Hsin-Ju Tang, Chia-Te Liao iD

European Heart Journal - Cardiovascular Pharmacotherapy · 2025

DOI: 10.1093/ehjcvp/pvae093 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Yu-Min Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Chi Mei Hospital, Chiali, Tainan City, 722, Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Atherosclerosis, Incretins. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atherosclerotic cardiovascular disease (ASCVD) encompasses various phenotypes with elevated risks of major adverse cardiovascular events (MACEs). This study aimed to assess the comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium–glucose cotransporter-2 inhibitors (SGLT2is) across diverse ASCVD phenotypes. Methods and results We conducted a systematic review and meta-analysis of randomized controlled trials evaluating GLP-1 RAs or SGLT2is against placebo or standard care in ASCVD patients. Primary outcomes included MACE, defined as cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke. Risk ratios (RRs) with 95% confidence interval (CI) were calculated using a random-effects model. Twenty-six trials (151 789 patients) were included. Both GLP-1 RAs and SGLT2is significantly reduced MACE rates in ASCVD patients (RR 0.85; 95% CI 0.80–0.91 for both). GLP-1 RAs showed significant effectiveness in peripheral artery disease (RR 0.86; 95% CI 0.76–0.98) and post-acute cardiovascular events (RR 0.90; 95% CI 0.83–0.97). In ASCVD with heart failure, both drug classes reduced MACE (GLP-1 RAs: RR 0.73; 95% CI 0.63–0.84; SGLT2is: RR 0.86; 95% CI 0.78–0.95). SGLT2is significantly reduced MACE in ASCVD with chronic kidney disease (RR 0.84; 95% CI 0.72–0.99), particularly in severe albuminuria (RR 0.61; 95% CI 0.37–0.99).

Conclusion

GLP-1 RAs and SGLT2is exhibit distinct cardiovascular effectiveness profiles across ASCVD phenotypes. GLP-1 RAs show particular benefits in peripheral artery disease and post-acute cardiovascular events, while SGLT2is demonstrate unique advantages in ASCVD with comorbid chronic kidney disease. Both are effective in heart failure. These findings support tailored treatment strategies for diverse ASCVD participants based on specific comorbidities and risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsAtherosclerosisIncretinsHumansTreatment OutcomeRandomized Controlled Trials as TopicPhenotypeMaleRisk AssessmentFemaleMiddle AgedAgedRisk FactorsGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

Atherosclerotic cardiovascular diseaseComparative effectivenessGlucagon-like peptide-1 receptor agonistsMajor adverse cardiovascular eventsSodium-–glucose cotransporter-2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsIncretinsGLP1R protein, humanGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Chi Mei Hospital, Chiali, Tainan City, 722, Taiwan.
  • Department of Nutrition, Chi Mei Medical Centre, Tainan City, 710, Taiwan.
  • Department of Public Health, College of Medicine, National Cheng Kung University, Tainan City, 704, Taiwan.
  • Department of Pharmacy, Chi Mei Medical Centre, Tainan City, 710, Taiwan.
  • Department of Internal Medicine, Chi Mei Medical Centre, Tainan City, 710, Taiwan.
  • Department of Intensive Care Medicine, Chi Mei Medical Centre, Tainan City, 710, Taiwan.

ORCID-Profile: Chia-Te Liao

Zitieren

APA

Lin, Y. M., Wu, J. Y., Lee, M. C., Su, C. L., Toh, H. S., Chang, W. T., Chen, S. Y., Kuo, F. H., Tang, H. J., & Liao, C. T. (2025). Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae093

Vancouver

Lin YM, Wu JY, Lee MC, Su CL, Toh HS, Chang WT, et al. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvae093

BibTeX
@article{Lin2025,
  author = {Lin, Yu-Min and Wu, Jheng-Yan and Lee, Mei-Chuan and Su, Chen-Lun and Toh, Han Siong and Chang, Wei-Ting and Chen, Sih-Yao and Kuo, Fang-Hsiu and Tang, Hsin-Ju and Liao, Chia-Te},
  title = {Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2025},
  doi = {10.1093/ehjcvp/pvae093}
}
Kostenlos starten →